Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size
Breast cancer is the leading type of cancer in Iranian women and affects them at least one decade younger than their counterparts in developed countries. Breast tumor progression and metastasis is accompanied by a decrease in the membranous expression of Syndecan-1 and an increase in its shedding. We measured the level of soluble Syndecan-1 in the sera of Iranian patients with breast cancer.
The study population included 61 chemotherapy-naïve breast cancer patients and 30 age/sex-matched healthy individuals. Blood was collected by venipuncture method and serum was separated, aliquoted and kept at −40 °C until used. A commercial ELISA was used to detect Syndecan-1 levels in the sera.
Soluble Syndecan-1 levels were increased in the sera of patients with breast cancer compared to healthy controls (87.89 ± 89.29 vs. 47.57 ± 46.46 ng/ml, p = 0.005). There was a positive correlation between soluble Syndecan-1 levels and tumor size (p = 0.017). The serum level of Syndecan-1 in patients without calcification showed a trend of increase compared to that of patients with calcification (108.80 ± 101.76 vs. 59.82 ± 57.13 ng/ml).
The positive correlation between soluble Syndecan-1 levels and tumor size in the present study highlights the importance of different varieties (cell-bound and soluble) of this molecule in the breast tumor progression and their significance as tumor biomarkers.
KeywordsBreast cancer Syndecan-1 Serum Tumor size
This work was performed as part of Sina Jelodar dissertation as a requirement for graduation as a general practitioner from Shiraz Medical School (Shiraz, Iran). This project was financially supported by a Grant (90-01-2779) from Shiraz University of Medical Sciences and was performed and supported by Shiraz Institute for Cancer Research, Shiraz, Iran (Grant ICR-100-502).
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- 2.WHO. Breast cancer: prevention and control. In: Organization WH, editor.Google Scholar
- 9.Purushothaman A, Sanderson RD. Atlas of genetics and cytogenetics in oncology and haematology. 2008 [cited 2016 September]. http://atlasgeneticsoncology.org/Genes/GC_SDC1.html.
- 12.Kharabi Masouleh B, Ten Dam GB, Wild MK, Seelige R, van der Vlag J, Rops AL, et al. Role of the heparan sulfate proteoglycan Syndecan-1 (CD138) in delayed-type hypersensitivity. J Immunol (Baltimore, Md: 1950). 2009;182(8):4985–93.Google Scholar
- 18.Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Can Res. 2001;61(14):5562–9.Google Scholar
- 33.The Human Protein Atlas [cited 2016 September]. http://www.proteinatlas.org/ENSG00000138798-EGF/tissue.
- 34.Yang N, Morrison CD, Liu P, Miecznikowski J, Bshara W, Han S, et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle (Georgetown, Tex). 2012;11(15):2922–30.Google Scholar